The METHYLOMIC project is advancing research to make personalised treatments for Crohn’s Disease (CD) and similar immune-mediated conditions a reality.
By building on previous studies, researchers have identified specific patterns in DNA methylation (a type of genetic marker) that can predict how well a patient will respond to certain biological therapies for CD. These markers, found in blood samples, have already been validated for three approved biological treatments, with prediction accuracy reaching up to 93% using advanced machine learning techniques.
- Objectives
-
The ultimate goal is to bring these discoveries into everyday clinical practice, helping doctors choose the best treatment for each patient. To achieve this, the project is working on a fast, precise test to detect these genetic markers, which will then be validated in a unique clinical trial. Alongside this, the project will assess the test’s cost-effectiveness and work with regulators to gain approval, aiming to deliver the first-ever personalised treatment kit for CD.
- EFCCA’s Role in Supporting Patients
-
EFCCA is actively contributing to the METHYLOMIC project by:
- Reviewing research proposals and patient information from a patient perspective to ensure they are clear and patient-friendly.
- Promoting the research among IBD communities in the countries involved.
- Sharing updates and project results through our networks to raise awareness and encourage patient participation.
- Workshops
-
Artificial Intelligence (AI) in IBD Care
On 21 October 2024, EFCCA and METHYLOMIC hosted the 'Artificial Intelligence (AI) in IBD Care' workshop, the first in a series of participatory events to be launched jointly within the framework of our Horizon Europe projects.
The event brought together patients, researchers and clinicians to explore the transformative potential of AI in understanding and treating IBD. Topics covered included an AI model designed to predict drug responses in Crohn's Disease, the application of AI in fibrosis and an overview by Roberto Saldaña (EFCCA’s Innovation and Patient Engagement Coordinator) on innovative AI uses within patient organisations. An engaging panel discussion with patients followed the presentations. The workshop is the first in a series of initiatives to reinforce the patient perspective in groundbreaking IBD research and offer a deeper understanding of advances in treatment, prediction and disease management.
Click here to watch the recorded session in You Tube.
To follow the progress of the METHYLOMIC project, visit their website or follow their X and LinkedIn profiles.
This groundbreaking initiative has the potential to transform the way Crohn’s Disease is treated, making therapies more effective and tailored to each patient’s unique needs.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101095449.